TTY Biopharm Co Ltd (4105) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TTY Biopharm Co Ltd (4105) has a cash flow conversion efficiency ratio of 0.097x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$778.89 Million ≈ $24.54 Million USD) by net assets (NT$8.05 Billion ≈ $253.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TTY Biopharm Co Ltd net asset quality index to measure how much of total assets are equity-financed.
TTY Biopharm Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how TTY Biopharm Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check TTY Biopharm Co Ltd (4105) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
TTY Biopharm Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TTY Biopharm Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Argus Shanghai Textile Chemicals Co Ltd
SHG:603790
|
0.021x |
|
Kangxin New Materials Co Ltd
SHG:600076
|
-0.009x |
|
Chipsea Technologies Shenzhen Corp Ltd
SHG:688595
|
-0.046x |
|
Chongqing QinAn M&E PLC
SHG:603758
|
0.030x |
|
OPUS GLOBAL Nyrt
BUD:OPUS
|
0.135x |
|
Shanghai Orient-Chip Technology Co. Ltd. A
SHG:688061
|
N/A |
|
Guangdong Great River Smarter Logistics Co Ltd Class A
SHE:002930
|
0.065x |
|
Ichitan Group Public Company Limited
BK:ICHI
|
0.193x |
Annual Cash Flow Conversion Efficiency for TTY Biopharm Co Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of TTY Biopharm Co Ltd from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see TTY Biopharm Co Ltd (4105) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$8.05 Billion ≈ $253.66 Million |
NT$1.76 Billion ≈ $55.51 Million |
0.219x | +21.80% |
| 2024-12-31 | NT$7.51 Billion ≈ $236.64 Million |
NT$1.35 Billion ≈ $42.51 Million |
0.180x | +7.70% |
| 2023-12-31 | NT$6.51 Billion ≈ $204.98 Million |
NT$1.09 Billion ≈ $34.19 Million |
0.167x | -15.86% |
| 2022-12-31 | NT$6.23 Billion ≈ $196.38 Million |
NT$1.24 Billion ≈ $38.93 Million |
0.198x | -8.99% |
| 2021-12-31 | NT$5.77 Billion ≈ $181.70 Million |
NT$1.26 Billion ≈ $39.58 Million |
0.218x | +151.55% |
| 2020-12-31 | NT$6.08 Billion ≈ $191.49 Million |
NT$526.35 Million ≈ $16.58 Million |
0.087x | -55.84% |
| 2019-12-31 | NT$6.17 Billion ≈ $194.36 Million |
NT$1.21 Billion ≈ $38.12 Million |
0.196x | +16.74% |
| 2018-12-31 | NT$6.39 Billion ≈ $201.37 Million |
NT$1.07 Billion ≈ $33.83 Million |
0.168x | +3.03% |
| 2017-12-31 | NT$6.11 Billion ≈ $192.55 Million |
NT$996.52 Million ≈ $31.40 Million |
0.163x | -- |
About TTY Biopharm Co Ltd
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It offers … Read more